BeiGene Ltd
(SHSE:688235)
Â¥
123
0.99 (0.81%)
Market Cap: 120.88 Bil
Enterprise Value: 108.32 Bil
PE Ratio: 0
PB Ratio: 4.85
GF Score: 55/100 - Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Beigene Ltd Investors and Analysts Panel Event Presentation TranscriptDec 11, 2023
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Beigene Ltd Investor Research and Development Day TranscriptJul 18, 2023
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2023
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation TranscriptDec 13, 2022
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call TranscriptDec 12, 2022
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Beigene Ltd at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Beigene Ltd R&D Day TranscriptAug 25, 2021
- Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call TranscriptJun 11, 2021
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call TranscriptDec 29, 2020
- Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call TranscriptJul 09, 2020
- Beigene Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call TranscriptMay 30, 2020
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Beigene Ltd Update Call: ASPEN Trial Readout TranscriptDec 16, 2019
- Beigene Ltd Corporate Update: Global Strategic Oncology Collaboration with Amgen TranscriptNov 01, 2019
- Beigene Ltd at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Beigene Ltd Update Call TranscriptSep 08, 2019
- Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) TranscriptJun 20, 2019
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Beigene Ltd at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Beigene Ltd Earnings Call TranscriptFeb 27, 2019Earnings
Beigene Ltd at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022 / 02:50PM GMT
Release Date Price:
Â¥114.5
(-1.45%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
And good morning, everybody, or good afternoon or even good evening in this case. Thank you once again for joining us for the 42nd Annual Cowen Healthcare Conference. I'm Yaron Werber, biotech analyst, and it's a great pleasure to moderate the next fireside chat with BeiGene. Today, we have with us John Oyler, who is the CEO; Julia Wang, who is the CFO; Lai Wang, who is the Global Head of R&D; and Kevin Mannix as well, who's VP of IR. So ladies and gentlemen, thanks for joining us. Always good to see you.
John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Thank you. Pleasure to be here.
Questions & Answers
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
So we have a half hour and BeiGene is becoming obviously a fairly big company with a huge pipeline and now 2 or actually 3 marketed products that you got approved and then
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)